Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
October 8, 2024 9:17 AM EDT
Stifel analyst Dae Gon ha reiterated a Buy rating and $74.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).
The analyst commented: "At face, today's FDA update on diazoxide choline-controlled release (DCCR) for Prader-Willi syndrome (PWS) comes as a... More
October 8, 2024 9:14 AM EDT
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $65.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).
The analyst commented: "This morning, Soleno announced that the FDA does not see a need to hold an advisory committee meeting to discuss DCCR ahead... More
October 8, 2024 8:31 AM EDT
Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a regulatory update from the U.S. Food and Drug Administration (FDA).
The FDA Review Division has determined that... More
